Free Trial

Schrödinger (SDGR) Competitors

Schrödinger logo
$25.67 +0.79 (+3.16%)
As of 10:00 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SDGR vs. LNTH, BBIO, TGTX, LEGN, SRPT, TLX, ADMA, BPMC, VRNA, and NUVL

Should you be buying Schrödinger stock or one of its competitors? The main competitors of Schrödinger include Lantheus (LNTH), BridgeBio Pharma (BBIO), TG Therapeutics (TGTX), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), Telix Pharmaceuticals Limited American Depositary Shares (TLX), ADMA Biologics (ADMA), Blueprint Medicines (BPMC), Verona Pharma (VRNA), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

Schrödinger vs.

Lantheus (NASDAQ:LNTH) and Schrödinger (NASDAQ:SDGR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, community ranking, profitability and media sentiment.

Lantheus has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Lantheus has a net margin of 28.57% compared to Schrödinger's net margin of -91.84%. Lantheus' return on equity of 44.29% beat Schrödinger's return on equity.

Company Net Margins Return on Equity Return on Assets
Lantheus28.57% 44.29% 23.52%
Schrödinger -91.84%-35.77%-24.51%

In the previous week, Lantheus had 14 more articles in the media than Schrödinger. MarketBeat recorded 20 mentions for Lantheus and 6 mentions for Schrödinger. Lantheus' average media sentiment score of 1.26 beat Schrödinger's score of 1.18 indicating that Lantheus is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lantheus
13 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Schrödinger
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lantheus has higher revenue and earnings than Schrödinger. Schrödinger is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lantheus$1.53B4.73$326.66M$4.3724.24
Schrödinger$207.54M8.76$40.72M-$2.57-9.68

Lantheus received 286 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 66.02% of users gave Lantheus an outperform vote while only 58.33% of users gave Schrödinger an outperform vote.

CompanyUnderperformOutperform
LantheusOutperform Votes
342
66.02%
Underperform Votes
176
33.98%
SchrödingerOutperform Votes
56
58.33%
Underperform Votes
40
41.67%

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 79.1% of Schrödinger shares are owned by institutional investors. 1.5% of Lantheus shares are owned by insiders. Comparatively, 8.6% of Schrödinger shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lantheus currently has a consensus target price of $129.43, indicating a potential upside of 22.19%. Schrödinger has a consensus target price of $32.80, indicating a potential upside of 31.83%. Given Schrödinger's higher possible upside, analysts clearly believe Schrödinger is more favorable than Lantheus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantheus
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Schrödinger
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.00

Summary

Lantheus beats Schrödinger on 13 of the 18 factors compared between the two stocks.

Get Schrödinger News Delivered to You Automatically

Sign up to receive the latest news and ratings for SDGR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SDGR vs. The Competition

MetricSchrödingerPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.82B$6.84B$5.53B$7.93B
Dividend YieldN/A3.05%5.11%4.23%
P/E Ratio-10.637.3222.5118.54
Price / Sales8.76241.49397.62103.30
Price / Cash37.4265.8538.1834.62
Price / Book3.276.486.734.25
Net Income$40.72M$143.41M$3.22B$248.18M
7 Day Performance-4.78%2.30%1.58%1.25%
1 Month Performance32.06%7.14%4.05%3.76%
1 Year Performance-1.50%-2.61%15.75%5.28%

Schrödinger Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SDGR
Schrödinger
2.4635 of 5 stars
$25.67
+3.2%
$32.80
+27.8%
-1.5%$1.88B$207.54M-11.03790Upcoming Earnings
Positive News
Gap Up
LNTH
Lantheus
3.9716 of 5 stars
$102.70
+0.9%
$129.43
+26.0%
+57.2%$7.03B$1.53B17.09700Upcoming Earnings
Positive News
BBIO
BridgeBio Pharma
4.5588 of 5 stars
$35.89
-1.2%
$53.00
+47.7%
+42.1%$6.81B$221.90M-12.59400Earnings Report
Analyst Forecast
Analyst Revision
News Coverage
TGTX
TG Therapeutics
3.3132 of 5 stars
$42.03
+1.7%
$40.67
-3.2%
+185.7%$6.67B$329.00M-420.26290Upcoming Earnings
Positive News
LEGN
Legend Biotech
2.6714 of 5 stars
$34.70
+1.2%
$78.82
+127.1%
-22.8%$6.37B$627.24M-36.531,070Positive News
SRPT
Sarepta Therapeutics
4.745 of 5 stars
$61.51
+1.8%
$158.70
+158.0%
-52.0%$5.97B$1.90B49.21840Upcoming Earnings
TLX
Telix Pharmaceuticals Limited American Depositary Shares
N/A$17.57
-6.5%
$22.00
+25.2%
N/A$5.94B$783.21M0.00N/AAnalyst Revision
News Coverage
Gap Down
High Trading Volume
ADMA
ADMA Biologics
1.4562 of 5 stars
$24.51
+12.1%
$22.50
-8.2%
+248.9%$5.82B$426.45M87.54530Upcoming Earnings
Options Volume
Positive News
High Trading Volume
BPMC
Blueprint Medicines
2.5415 of 5 stars
$88.51
+1.0%
$124.53
+40.7%
+4.6%$5.66B$508.82M-81.95640Earnings Report
Analyst Forecast
News Coverage
Positive News
VRNA
Verona Pharma
2.7155 of 5 stars
$68.83
+5.1%
$78.50
+14.0%
+374.8%$5.56B$42.28M-35.8530Earnings Report
Analyst Forecast
Insider Trade
Short Interest ↓
Analyst Revision
News Coverage
Positive News
NUVL
Nuvalent
1.7173 of 5 stars
$75.20
+2.3%
$115.50
+53.6%
+7.9%$5.38BN/A-21.6740Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:SDGR) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners